For immediate release: October 21, 2004
VANCOUVER – Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) announced today that it will hold a conference call and webcast on Thursday, October 28, 2004 at 9:00 a.m. PST (12:00 noon EST) to discuss third quarter 2004 operating results and to provide an update on developments at the Company.
To participate in the conference call, please dial 416-405-8532 or 1-877-295-2825. The call will be available for replay until November 4, 2004 by calling 416-695-5800 or 1-800-408-3053 and entering the pass code 3107465#.
The live or archived webcast can be accessed through the Company’s website at www.inexpharm.com.
INEX is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer.
INEX’s lead product is Marqibo™ (formerly referred to as Onco TCS), a proprietary drug comprised of the widely used off-patent anticancer drug vincristine encapsulated in INEX’s liposomal drug delivery technology. INEX is commercializing Marqibo™ in North America with partner Enzon Pharmaceuticals Inc. A New Drug Application (NDA) for Marqibo™ has been accepted by the FDA with a target date of January 15, 2005 for completion of the review. As part of the review process, Marqibo™ will be presented at the December 1, 2004 meeting of the Oncologic Drugs Advisory Committee (ODAC). The NDA is seeking marketing approval for Marqibo™ as a single-agent treatment for patients with relapsed aggressive non-Hodgkin’s lymphoma (NHL) previously treated with at least two combination chemotherapy regimens.
INEX investor contact:
Ian Mortimer
Senior Director, Investor Relations
Inex Pharmaceuticals Corporation
Tel: 604.419.3200
Email: info@inexpharm.com
Website: www.inexpharm.com
INEX media contact:
Miriam Zitner
James Hoggan & Associates Inc.
Tel: 604.739.7500
Email: mzitner@hoggan.com
